Post-Licensure Observational Study of the Safety of GARDASIL in Males.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 12 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 12 May 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 11 Apr 2012 New trial record